François‐Xavier Mathy

UCB Pharma (Belgium) BE

Publications

959

Citations

H-Index

i10-Index

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

In Vivo Methods for the Assessment of Topical Drug Bioavailability OA

Christophe Herkenne, Ingo Alberti, Aarti Naik, Yogeshvar N. Kalia, François‐Xavier Mathy +2 more

Pharmaceutical Research 2007

252

Drug metabolism and pharmacokinetics OA

M. Strolin Benedetti, Rhys Whomsley, Italo Poggesi, Willi Cawello, François‐Xavier Mathy +3 more

Drug Metabolism Reviews 2009

191

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action OA

Jean‐Marie Nicolas, Jonas Hannestad, Daniel Holden, Sophie Kervyn, Nabeel Nabulsi +10 more

Epilepsia 2015

164

Development of lacosamide for the treatment of partial‐onset seizures OA

Pamela Doty, David Hébert, François‐Xavier Mathy, William Byrnes, J. Zackheim +1 more

Annals of the New York Academy of Sciences 2013

Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease OA

Johan W. Smit, Peter Basile, Maria Key Prato, Laurent Detalle, François‐Xavier Mathy +8 more

Movement Disorders 2022

Publications

19 total

Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599) PDF

Joël Mercier, Massimo Bani, Anny‐Odile Colson, Massimiliano Germani, Marianna Lalla et al. - Molecular Imaging and Biology, 2023

Cited by 10 OpenAlex

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study OA

A. Delaunois, F. Mathy, M. Cornet, V. Gryshkova, Chloé Korlowski - Pharmacology Research & Perspectives, 2023

Cited by 1 Semantic Scholar

Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease PDF

Johan W. Smit, Peter Basile, Maria Key Prato, Laurent Detalle, François‐Xavier Mathy et al. - Movement Disorders, 2022

Cited by 56 OpenAlex

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease OA

J. Smit, Peter Basile, Maria Key Prato, L. Detalle, F. Mathy - Movement Disorders, 2022

Cited by 47 Semantic Scholar

Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions

Jean‐Marie Nicolas, Hugues Chanteux, Johan Nicolaï, Frédéric Brouta, Delphine Viot et al. - European Journal of Pharmaceutical Sciences, 2019

Cited by 7 OpenAlex

Drug–drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants PDF

François‐Xavier Mathy, Elisabeth Dohin, François Bonfitto, Barbara Pelgrims - European Heart Journal, 2018

Cited by 26 OpenAlex

Pharmacokinetics and metabolism of [14C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers

Valérie Mancel, F. Mathy, P. Boulanger, Stephen English, M. Croft - Xenobiotica; the fate of foreign compounds in biological systems, 2017

Cited by 8 Semantic Scholar

Pharmacokinetics and metabolism of [<sup>14</sup>C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers

Valérie Mancel, François‐Xavier Mathy, Pierre Boulanger, Stephen English, Marie Croft et al. - Xenobiotica, 2016

Cited by 10 OpenAlex

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action PDF

Jean‐Marie Nicolas, Jonas Hannestad, Daniel Holden, Sophie Kervyn, Nabeel Nabulsi et al. - Epilepsia, 2015

Cited by 164 OpenAlex

An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome OA

J. Elshoff, W. Cawello, J. Andreas, F. Mathy, M. Braun - Drugs, 2015

Cited by 79 Semantic Scholar

Research Topics

Drug Transport and Resistance Mechanisms (5) Advancements in Transdermal Drug Delivery (5) Dermatology and Skin Diseases (5) Neuroscience and Neuropharmacology Research (3) Parkinson's Disease Mechanisms and Treatments (3)

Frequent Co-Authors

VÉ

Véronique Préat

6 joint publications

Roger K. Verbeeck

5 joint publications

Massimo Bani

3 joint publications

M. Strolin Benedetti

2 joint publications

Rhys Whomsley

2 joint publications

Jean‐Marie Nicolas

2 joint publications

Affiliations

UCB Pharma (Belgium)

BE 2023 - 2007

UCLouvain

BE 2007 - 2001

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers

François‐Xavier Mathy

Publication & Citation Trends

Most Cited Works

Publications

Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599) PDF

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study OA

Phase 1/1b Studies of <scp>UCB0599</scp>, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease PDF

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease OA

Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions

Drug–drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants PDF

Pharmacokinetics and metabolism of [14C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers

Pharmacokinetics and metabolism of [<sup>14</sup>C]-tozadenant (SYN-115), a novel A2a receptor antagonist ligand, in healthy volunteers

Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (<scp>SV</scp>2A) ligand with preclinical evidence of high brain permeability and fast onset of action PDF

An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome OA

Research Topics

Frequent Co-Authors

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back